News for Adicet Bio, Inc. (ACET)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio (ACET) appoints Michael Grissinger with over 40 years of business development expertise to its Board of Directors. Grissinger brings signific

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where Adicet Bio, Inc.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. ( HOWL), an innovative biopharmaceutical company pioneering the development of

**media[548365]**

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Julie Maltzman appointed as Chief Medical Officer of Adicet Bio, leading clinical development strategy for autoimmune and oncology pipeline.

Adicet Bio Inc. (ACET) experienced a significant stock price drop of 5.43%, trading at $0.965 per share with a volume of 279,487 shares and a turnover rate of 0

Adicet Bio Inc. (ACET) experienced a significant stock movement, dropping 5.45% to $1.04 per share. The trading volume reached 409,983 shares with a turnover ra

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio begins trial for innovative cancer therapy

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

FDA greenlights Adicet Bio's trial expansion for autoimmune diseases

Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<